Research & Literature

The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.

Carbone M, Sharp SJ, Flack S, et al.

Hepatology (Baltimore, Md.) 2016; (63(3)):930-50 doi:10.1002/hep.28017.

[Bone disease in primary biliary cirrhosis].

Shibata H, Nakao K

Clinical calcium 2015; (25(11)):1633-8.

[Clinical guidelines for bone disease in primary biliary cirrhosis].

Ishibashi H, Komori A

Clinical calcium 2015; (25(11)):1675-80.

Proposed therapies in primary biliary cholangitis.

Floreani A, Sun Y, Zou ZS, et al.

Expert review of gastroenterology & hepatology 2016; (10(3)):371-382 doi:10.1586/17474124.2016.1121810.

Pathogenesis and Management of Pruritus in PBC and PSC.

Kremer AE, Namer B, Bolier R, et al.

Digestive diseases (Basel, Switzerland) 2015; (33 Suppl 2()):164-75 doi:10.1159/000440829.

Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.

van Buuren HR, Lammers WJ, Harms MH, Hansen BE

Digestive diseases (Basel, Switzerland) 2015; (33 Suppl 2()):118-24 doi:10.1159/000440759.

[THE ROLE OF NUTRITION IN THE GENESIS OF-HEPATIC OSTEODYSTROPHY IN PRIMARY BILIARY CIRRHOSIS].

Prashnova MK, Raikhelson KL, Ivanova OE, et al.

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 2015; 30-3.

A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis.

Silveira MG, Gossard AA, Stahler AC, et al.

American journal of therapeutics 2017; (24(2)):e167-e176 doi:10.1097/MJT.0000000000000387.

Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach.

Mousa HS, Carbone M, Malinverno F, et al.

Autoimmunity reviews 2016; (15(9)):870-6.

[Environmental factors and primary biliary cirrhosis].

Chen LP, Zhao H, Lyu B, Cheng JL

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2016; (24(7)):541-544 doi:10.3760/cma.j.issn.1007-3418.2016.07.014.

Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review.

Trivedi HD, Lizaola B, Tapper EB, Bonder A

The American journal of medicine 2017; (130(6)):744.e1-744.e7 doi:10.1016/j.amjmed.2017.01.037.

The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature.

de Liso F, Matinato C, Ronchi M, Maiavacca R

Clinical chemistry and laboratory medicine 2017; (56(1)):25-31.

A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.

Hegade VS, Bolier R, Oude Elferink RP, et al.

Frontline gastroenterology 2016; (7(3)):158-166 doi:10.1136/flgastro-2015-100618.

Association between primary biliary cholangitis and osteoporosis: meta-analysis.

Fan J, Wang Q, Sun L

Clinical rheumatology 2017; (36(11)):2565-2571 doi:10.1007/s10067-017-3844-x.

[How to understand the clinical significance of autoantibodies in primary biliary cholangitis].

Yan HP, Zhang HP, Chen XX

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2017; (25(11)):810-815 doi:10.3760/cma.j.issn.1007-3418.2017.11.003.

[Primary biliary cholangitis-established and novel therapies].

Vetter M, Kremer AE

Der Internist 2018; (59(6)):544-550 doi:10.1007/s00108-018-0427-0.

Evolution of our understanding of PBC.

Tanaka A, Leung PSC, Gershwin ME

Best practice & research. Clinical gastroenterology 2018; (34-35()):3-9 doi:10.1016/j.bpg.2018.05.008.

Symptoms of PBC - Pathophysiology and management.

Khanna A, Leighton J, Lee Wong L, Jones DE

Best practice & research. Clinical gastroenterology 2018; (34-35()):41-47 doi:10.1016/j.bpg.2018.06.007.

Risk stratification and prognostic modelling in primary biliary cholangitis.

Goet JC, Harms MH, Carbone M, Hansen BE

Best practice & research. Clinical gastroenterology 2018; (34-35()):95-106 doi:10.1016/j.bpg.2018.06.006.

Obeticholic acid in primary biliary cholangitis: where we stand.

Manne V, Kowdley KV

Current opinion in gastroenterology 2019; (35(3)):191-196 doi:10.1097/MOG.0000000000000525.

Comparison of Sertraline with Rifampin in the treatment of Cholestatic Pruritus: A Randomized Clinical Trial.

Ataei S, Kord L, Larki A, et al.

Reviews on recent clinical trials 2019; (14(3)):217-223 doi:10.2174/1574887114666190328130720.

Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.

Zhang Q, Liu Z, Wu S, et al.

Gastroenterology research and practice 2019; (2019()):8959103 doi:10.1155/2019/8959103.

Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC).

Kaps L, Grambihler A, Yemane B, et al.

Digestive diseases and sciences 2020; (65(10)):3006-3013 doi:10.1007/s10620-019-06009-3.

Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges.

Trivedi HD, Danford CJ, Goyes D, Bonder A

Clinical and experimental gastroenterology 2020; (13()):17-24 doi:10.2147/CEG.S204638.

Concurrence of multiple sclerosis and primary biliary cholangitis: Report of 3 cases.

Sattar M, Poursadeghfard M

Caspian journal of internal medicine 2020; (11(2)):223-226 doi:10.22088/cjim.11.2.223.

Use of Butorphanol as Treatment for Cholestatic Itch.

Golpanian RS, Yosipovitch G, Levy C

Digestive diseases and sciences 2021; (66(5)):1693-1699 doi:10.1007/s10620-020-06392-2.

Role of Antinuclear Antibodies in Primary Biliary Cholangitis.

Levy C, Bowlus CL

The American journal of gastroenterology 2020; (115(10)):1604-1606 doi:10.14309/ajg.0000000000000765.

Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Natarajan Y, Tansel A, Patel P, et al.

Digestive diseases and sciences 2021; (66(7)):2439-2451 doi:10.1007/s10620-020-06498-7.

Early histopathologic changes in primary biliary cholangitis: does 'minimal change' primary biliary cholangitis exist? A pathologist's view.

Chatzipantelis P, Giatromanolaki A

European journal of gastroenterology & hepatology 2021; (33(12)):e7-e12 doi:10.1097/MEG.0000000000001876.

Understanding Fatigue in Primary Biliary Cholangitis.

Phaw NA, Dyson JK, Mells G, Jones D

Digestive diseases and sciences 2021; (66(7)):2380-2386 doi:10.1007/s10620-020-06502-0.

Managing cognitive symptoms and fatigue in cholestatic liver disease.

Phaw NA, Leighton J, Dyson JK, Jones DE

Expert review of gastroenterology & hepatology 2021; (15(3)):235-241 doi:10.1080/17474124.2021.1844565.

Prevalence of Celiac Disease in Patients with Primary Biliary Cholangitis.

Callichurn K, Cvetkovic L, Therrien A, et al.

Journal of the Canadian Association of Gastroenterology 2021; (4(1)):44-47 doi:10.1093/jcag/gwz039.

Non-invasive diagnosis and follow-up of primary biliary cholangitis.

Corpechot C, Heurgue A, Tanne F, et al.

Clinics and research in hepatology and gastroenterology 2022; (46(1)):101770 doi:10.1016/j.clinre.2021.101770.

Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life.

Sivakumar T, Kowdley KV

Hepatic medicine : evidence and research 2021; (13()):83-92 doi:10.2147/HMER.S256692.

Antimitochondrial Antibodies: from Bench to Bedside.

Colapietro F, Lleo A, Generali E

Clinical reviews in allergy & immunology 2022; (63(2)):166-177 doi:10.1007/s12016-021-08904-y.

Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis.

Fujinaga Y, Namisaki T, Takaya H, et al.

Medicine 2021; (100(39)):e27403 doi:10.1097/MD.0000000000027403.

The Causal Effects of Primary Biliary Cholangitis on Thyroid Dysfunction: A Two-Sample Mendelian Randomization Study.

Huang P, Hou Y, Zou Y, et al.

Frontiers in genetics 2021; (12()):791778 doi:10.3389/fgene.2021.791778.

Widespread gaps in the quality of care for primary biliary cholangitis in UK.

Sivakumar M, Gandhi A, Shakweh E, et al.

Frontline gastroenterology 2022; (13(1)):32-38 doi:10.1136/flgastro-2020-101713.

Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases.

Xing M, Gao M, Li J, et al.

Medicine 2022; (101(1)):e28443 doi:10.1097/MD.0000000000028443.

[Primary biliary cholangitis].

Soret PA, Chazouillères O, Corpechot C

La Revue du praticien 2021; (71(8)):885-891.

Immunoglobulin M: A Neglected Serum Biomarker in Treatment-Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase.

Ding D, Xuan G, Hu Y, et al.

Hepatology communications 2022; (6(6)):1403-1412 doi:10.1002/hep4.1907.

Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.

Chen S, Li MQ, Duan WJ, et al.

Hepatobiliary & pancreatic diseases international : HBPD INT 2022; (21(6)):577-582 doi:10.1016/j.hbpd.2022.05.009.

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.

Corpechot C, Carrat F, Gaouar F, et al.

Journal of hepatology 2022; (77(6)):1545-1553 doi:10.1016/j.jhep.2022.06.017.

Roles of Non-Coding RNAs in Primary Biliary Cholangitis.

Zhang Y, Jiao Z, Chen M, et al.

Frontiers in molecular biosciences 2022; (9()):915993 doi:10.3389/fmolb.2022.915993.

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

Wang C, Shi Y, Wang X, et al.

Frontiers in immunology 2022; (13()):940688 doi:10.3389/fimmu.2022.940688.

Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

de Veer RC, van Hooff MC, Corpechot C, et al.

The American journal of gastroenterology 2023; (118(7)):1196-1203 doi:10.14309/ajg.0000000000002128.

Prognostic modeling in biliary diseases.

Ciobanu C, Russo MW

Current opinion in gastroenterology 2023; (39(2)):89-94 doi:10.1097/MOG.0000000000000911.

[Diagnosis and Treatment of Primary Biliary Cholangitis].

Kim KA

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2023; (81(2)):86-90 doi:10.4166/kjg.2023.002.

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Corpechot C, Lemoinne S, Soret PA, et al.

Hepatology (Baltimore, Md.) 2024; (79(1)):39-48 doi:10.1097/HEP.0000000000000529.

Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis.

Medford A, Childs J, Little A, et al.

Journal of clinical and translational hepatology 2023; (11(4)):949-957 doi:10.14218/JCTH.2022.00398.

Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.

Chen JL, Liu Y, Bi YF, Wang XB

World journal of gastroenterology 2023; (29(29)):4580-4592 doi:10.3748/wjg.v29.i29.4580.

High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.

Zhu H, Zheng M, He H, et al.

BMC gastroenterology 2023; (23(1)):400 doi:10.1186/s12876-023-03031-8.

New Therapies on the Horizon for Primary Biliary Cholangitis.

Tanaka A

Drugs 2024; (84(1)):1-15 doi:10.1007/s40265-023-01979-1.

Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.

Kremer AE, Mayo MJ, Hirschfield GM, et al.

Hepatology (Baltimore, Md.) 2024; (80(1)):27-37 doi:10.1097/HEP.0000000000000728.

Autotaxin: A Potential biomarker for primary biliary cholangitis.

Yang Y, Liu B, Zang B, et al.

Heliyon 2024; (10(1)):e23438 doi:10.1016/j.heliyon.2023.e23438.

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

Hirschfield GM, Bowlus CL, Mayo MJ, et al.

The New England journal of medicine 2024; (390(9)):783-794 doi:10.1056/NEJMoa2312100.

Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma.

Floreani A, Gabbia D, De Martin S

International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25042194.

Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk.

Liang Y, Li J, Zhang Z, et al.

Clinics and research in hepatology and gastroenterology 2024; (48(5)):102321 doi:10.1016/j.clinre.2024.102321.

Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization.

Ma G, Yang J, Wang X, et al.

Scientific reports 2024; (14(1)):11528 doi:10.1038/s41598-024-62509-x.

Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.

von Maltzahn R, Mayo MJ, Smith HT, et al.

Journal of patient-reported outcomes 2024; (8(1)):60 doi:10.1186/s41687-024-00722-y.

Plasma Exchange for Refractory Pruritus Due to Drug-Induced Chronic Cholestasis Following Azithromycin Misuse in COVID-19 Infection.

Mongare N, Orare K, Busaidy S, et al.

Cureus 2024; (16(5)):e60884 doi:10.7759/cureus.60884.

Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.

Lam L, Soret PA, Lemoinne S, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024; (22(12)):2432-2441.e2 doi:10.1016/j.cgh.2024.06.035.

The treatment of primary biliary cholangitis: from shadow to light.

Sylvia D, Tomas K, Marian M, et al.

Therapeutic advances in gastroenterology 2024; (17()):17562848241265782 doi:10.1177/17562848241265782.

Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis.

An J, Chon YE, Kim G, et al.

Clinical and molecular hepatology 2024; (30(Suppl)):S134-S146 doi:10.3350/cmh.2024.0586.

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.

Roberts SB, Choi WJ, Worobetz L, et al.

JHEP reports : innovation in hepatology 2024; (6(10)):101168 doi:10.1016/j.jhepr.2024.101168.

Seladelpar: First Approval.

Hoy SM

Drugs 2024; (84(11)):1487-1495 doi:10.1007/s40265-024-02114-4.

Symptom Reporting in Patients with Primary Biliary Cholangitis: Higher Burden of Symptom Detection Using an Interactive App.

Daza J, Espinosa-Montagut N, Kautz A, et al.

Digestive diseases (Basel, Switzerland) 2025; (43(2)):170-178 doi:10.1159/000543229.

Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review.

Kanda T, Sasaki-Tanaka R, Kimura N, et al.

International journal of molecular sciences 2025; (26(5)) doi:10.3390/ijms26051883.

Validation of PBC-10 in Japanese patients with primary biliary cholangitis.

Takeuchi A, Abe M, Furukawa S, et al.

Hepatology research : the official journal of the Japan Society of Hepatology 2025; (55(7)):986-993 doi:10.1111/hepr.14199.

Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.

Alvaro D, Calvaruso V, Carbone M, et al.

Liver international : official journal of the International Association for the Study of the Liver 2025; (45(6)):e70118 doi:10.1111/liv.70118.

A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines.

Worthington J, He E, Caruana M, et al.

MDM policy & practice 2025; (10(1)):23814683251344962 doi:10.1177/23814683251344962.

GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.

Li SX, Li BE, Li M, et al.

Journal of digestive diseases 2025; (26(5-6)):250-259 doi:10.1111/1751-2980.13359.

Gut Microbiota: Implications in Pathogenesis and Potential Therapeutic Target in Primary Biliary Cholangitis.

Nie Y, Shi Y, Yang Y

Journal of clinical and translational hepatology 2025; (13(9)):776-784 doi:10.14218/JCTH.2025.00212.

Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.

George J, Allard NL, Roberts SK, et al.

The Medical journal of Australia 2025; (223(8)):426-436 doi:10.5694/mja2.70061.

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Wong YJ, Lam L, Soret PA, et al.

Journal of hepatology 2026; (84(2)):275-283 doi:10.1016/j.jhep.2025.09.024.

Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.

Martins A, Khakoo NS, Reddy A, et al.

Hepatology (Baltimore, Md.) 2025; doi:10.1097/HEP.0000000000001465.

Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapy.

Stein K, Hofmann WP, Franke A, et al.

Zeitschrift fur Gastroenterologie 2025; (63(12)):1260-1267 doi:10.1055/a-2721-1160.

Variation in microbiome and metabolites is associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus.

Zhou Y, Ying G, Shen W, et al.

Microbiology spectrum 2026; (14(2)):e0074725 doi:10.1128/spectrum.00747-25.

Seladelpar Improves Cholestasis and Pruritus in Obeticholic Acid and Fibrate-experienced Patients With Primary Biliary Cholangitis.

Gordon SC, Proehl S, Pratt D, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026; doi:10.1016/j.cgh.2026.01.011.